This educational guide is part of the additional risk minimisation measures for idecabtagene vicleucel and contains information regarding selected idecabtagene vicleucel-associated adverse reactions of cytokine release syndrome (CRS), neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) and secondary malignancy of T-cell origin. These are not all the adverse reactions associated with idecabtagene vicleucel. Please refer to the idecabtagene vicleucel SmPC for more information.

The Patient Card is an important document that should be carried by the patient at all times. It contains key information, including symptoms that the patient should be aware of and look out for.